

Table 4.26

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	274,083	99.4%	223,374	99.5%	28,137	99.3%	19,006	99.3%	1,020	99.0%	26,040	99.2%
Epidermoid carcinoma ^d (8051-8131)	158	0.1%	126	0.1%	22	0.1%	-	-	-	-	19	0.1%
Adenocarcinoma ^e	268,077	97.2%	218,822	97.4%	27,123	95.7%	18,669	97.6%	995	96.6%	25,408	96.8%
Adenocarcinoma, NOS (8140)	2,371	0.9%	1,895	0.8%	297	1.0%	130	0.7%	-	-	220	0.8%
Infiltrating duct carcinoma (8500)	197,393	71.6%	159,122	70.9%	21,017	74.2%	14,699	76.8%	760	73.8%	19,098	72.7%
Lobular carcinoma, NOS (8520)	23,275	8.4%	20,269	9.0%	1,774	6.3%	956	5.0%	64	6.2%	1,811	6.9%
Inflammatory adenocarcinoma (8530)	1,399	0.5%	1,090	0.5%	241	0.9%	53	0.3%	-	-	187	0.7%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	28,176	10.2%	24,004	10.7%	2,219	7.8%	1,604	8.4%	102	9.9%	2,673	10.2%
Mucinous adenocarcinoma (8480,8482)	6,104	2.2%	4,878	2.2%	571	2.0%	567	3.0%	21	2.0%	502	1.9%
Mucin-producing adenocarcinoma (8481)	98	0.0%	78	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	2,605	0.9%	2,351	1.0%	133	0.5%	94	0.5%	-	-	176	0.7%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,595	0.6%	1,120	0.5%	278	1.0%	172	0.9%	-	-	182	0.7%
Paget disease (8540-8543)	1,504	0.5%	1,206	0.5%	159	0.6%	117	0.6%	-	-	179	0.7%
Other adenocarcinomas ^f	3,557	1.3%	2,809	1.3%	420	1.5%	273	1.4%	-	-	372	1.4%
Other specific carcinomas ^g	2,563	0.9%	1,865	0.8%	519	1.8%	149	0.8%	-	-	294	1.1%
Medullary adenocarcinoma (8510-8513)	1,147	0.4%	769	0.3%	295	1.0%	69	0.4%	-	-	152	0.6%
Other ^h	1,416	0.5%	1,096	0.5%	224	0.8%	80	0.4%	-	-	142	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	3,285	1.2%	2,561	1.1%	473	1.7%	180	0.9%	-	-	319	1.2%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	300	0.1%	242	0.1%	35	0.1%	18	0.1%	-	-	25	0.1%
Hemangiosarcomas (9120-9126,9170)	146	0.1%	134	0.1%	-	-	-	-	-	-	-	-
Other sarcomas ^d	154	0.1%	108	0.0%	31	0.1%	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	727	0.3%	544	0.2%	89	0.3%	81	0.4%	-	-	139	0.5%
Phyllodes tumor, malignant (9020)	597	0.2%	449	0.2%	61	0.2%	75	0.4%	-	-	122	0.5%
Other ^e	130	0.0%	95	0.0%	28	0.1%	-	-	-	-	17	0.1%
Unspecified (8000-8005)	568	0.2%	427	0.2%	74	0.3%	32	0.2%	-	-	49	0.2%
Total ^f	275,678	100.0%	224,587	100.0%	28,335	100.0%	19,137	100.0%	1,030	100.0%	26,253	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.27

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	69,788	99.7%	55,680	99.7%	6,974	99.6%	6,009	99.8%	185	100.0%	6,075	99.8%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^f	58,818	84.0%	46,439	83.2%	6,074	86.8%	5,471	90.9%	154	83.2%	5,172	85.0%
Cribriform carcinoma <i>in situ</i> (8201/2)	5,743	8.2%	4,477	8.0%	578	8.3%	587	9.8%	23	12.4%	551	9.1%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	4,094	5.8%	3,369	6.0%	323	4.6%	350	5.8%	-	-	329	5.4%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	23,106	33.0%	18,534	33.2%	2,403	34.3%	1,839	30.6%	59	31.9%	1,904	31.3%
Comedocarcinoma <i>in situ</i> (8501/2)	5,142	7.3%	4,108	7.4%	537	7.7%	429	7.1%	-	-	471	7.7%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,142	1.6%	799	1.4%	191	2.7%	122	2.0%	-	-	110	1.8%
Noninfiltrating intracystic carcinoma(8504/2)	323	0.5%	213	0.4%	48	0.7%	56	0.9%	-	-	28	0.5%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,629	2.3%	1,300	2.3%	190	2.7%	113	1.9%	-	-	140	2.3%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	17,444	24.9%	13,482	24.1%	1,788	25.5%	1,955	32.5%	30	16.2%	1,617	26.6%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	7,953	11.4%	6,783	12.1%	597	8.5%	329	5.5%	20	10.8%	649	10.7%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	7,927	11.3%	6,760	12.1%	594	8.5%	329	5.5%	20	10.8%	649	10.7%
Lobular CIS ^f with other CIS ^f (8524/2)	25	0.0%	23	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,500	3.6%	2,068	3.7%	234	3.3%	160	2.7%	-	-	218	3.6%
Other adenocarcinomas ^g	505	0.7%	379	0.7%	69	1.0%	48	0.8%	-	-	36	0.6%
Other <i>in situ</i> histologies ^h	209	0.3%	167	0.3%	27	0.4%	-	-	-	-	-	-
Total	69,997	100.0%	55,847	100.0%	7,001	100.0%	6,019	100.0%	185	100.0%	6,088	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^f CIS = Carcinoma *in situ*.

^g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	16,646	98.2%	12,566	98.2%	2,288	98.0%	1,427	98.7%	110	97.3%	3,787	98.3%
Epidermoid carcinoma ^d (8050-8131)	11,382	67.1%	8,379	65.5%	1,809	77.5%	945	65.4%	83	73.5%	2,655	68.9%
Squamous cell carcinoma (8070)	7,646	45.1%	5,558	43.4%	1,324	56.7%	606	41.9%	55	48.7%	1,594	41.4%
Squamous cell, keratinizing (8071)	1,249	7.4%	933	7.3%	193	8.3%	103	7.1%	-	-	348	9.0%
Squamous cell, non-keratinizing (8072)	1,520	9.0%	1,162	9.1%	185	7.9%	140	9.7%	-	-	450	11.7%
Squamous cell, Microinvasive (8076)	715	4.2%	548	4.3%	66	2.8%	69	4.8%	-	-	205	5.3%
Other (8050-8069, 8073-8075,8077-8131)	252	1.5%	178	1.4%	41	1.8%	27	1.9%	-	-	58	1.5%
Adenocarcinoma ^e	4,508	26.6%	3,655	28.6%	339	14.5%	424	29.3%	19	16.8%	969	25.2%
Adenocarcinoma, NOS (8140)	2,358	13.9%	1,921	15.0%	170	7.3%	215	14.9%	-	-	512	13.3%
Adenosquamous (8560,8570)	704	4.2%	552	4.3%	71	3.0%	71	4.9%	-	-	177	4.6%
Other adenocarcinomas ^f	1,446	8.5%	1,182	9.2%	98	4.2%	138	9.5%	-	-	280	7.3%
Other specific carcinomas ^g	248	1.5%	182	1.4%	35	1.5%	26	1.8%	-	-	54	1.4%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	508	3.0%	350	2.7%	105	4.5%	32	2.2%	-	-	109	2.8%
Sarcoma ^h	81	0.5%	63	0.5%	-	-	-	-	-	-	22	0.6%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	150	0.9%	109	0.9%	25	1.1%	-	-	-	-	25	0.6%
Unspecified (8000-8005)	75	0.4%	59	0.5%	-	-	-	-	-	-	18	0.5%
Total	16,952	100.0%	12,797	100.0%	2,335	100.0%	1,446	100.0%	113	100.0%	3,852	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	183,623	99.5%	146,739	99.5%	20,915	99.5%	13,258	99.5%	841	98.8%	16,784	99.5%
Epidermoid carcinoma ^d (8051-8131)	955	0.5%	800	0.5%	118	0.6%	-	-	-	-	79	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	896	0.5%	749	0.5%	112	0.5%	-	-	-	-	72	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	173,461	94.0%	139,639	94.7%	19,213	91.4%	12,362	92.8%	787	92.5%	15,683	93.0%
Adenocarcinoma, NOS (8140)	119,580	64.8%	95,986	65.1%	13,381	63.6%	8,829	66.3%	587	69.0%	10,773	63.9%
Adenocarcinoma in adenomatous polyp (8210)	13,927	7.5%	11,116	7.5%	1,376	6.5%	1,120	8.4%	57	6.7%	1,198	7.1%
Adenocarcinoma in villous adenoma (8261)	5,363	2.9%	4,351	3.0%	572	2.7%	369	2.8%	21	2.5%	582	3.4%
Mucinous adenocarcinoma (8470-8473,8480,8482)	12,571	6.8%	10,477	7.1%	1,281	6.1%	704	5.3%	41	4.8%	1,216	7.2%
Mucin-producing adenocarcinoma (8481)	2,964	1.6%	2,400	1.6%	412	2.0%	134	1.0%	-	-	259	1.5%
Signet ring adenocarcinoma (8490)	2,052	1.1%	1,716	1.2%	169	0.8%	150	1.1%	-	-	188	1.1%
Other adenocarcinomas ^e	17,004	9.2%	13,593	9.2%	2,022	9.6%	1,056	7.9%	67	7.9%	1,467	8.7%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	7,490	4.1%	4,959	3.4%	1,362	6.5%	763	5.7%	37	4.3%	866	5.1%
Neuroendocrine carcinoid (8240-8245)	6,174	3.3%	3,877	2.6%	1,220	5.8%	685	5.1%	31	3.6%	753	4.5%
Other ^f	1,316	0.7%	1,082	0.7%	142	0.7%	78	0.6%	-	-	113	0.7%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,717	0.9%	1,341	0.9%	222	1.1%	118	0.9%	-	-	156	0.9%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	96	0.1%	75	0.1%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	238	0.1%	172	0.1%	32	0.2%	31	0.2%	-	-	24	0.1%
Unspecified (8000-8005)	564	0.3%	461	0.3%	64	0.3%	23	0.2%	-	-	51	0.3%
Total ^d	184,521	100.0%	147,447	100.0%	21,024	100.0%	13,319	100.0%	851	100.0%	16,872	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	17,692	99.1%	14,792	99.1%	1,985	99.4%	739	98.8%	76	100.0%	1,188	98.8%
Epidermoid carcinoma ^d (8051-8131)	6,120	34.3%	3,921	26.3%	1,621	81.2%	517	69.1%	31	40.8%	474	39.4%
Squamous cell carcinoma (8070-8078, 8083-8084)	6,106	34.2%	3,909	26.2%	1,619	81.1%	517	69.1%	31	40.8%	473	39.4%
Adenocarcinoma ^e	10,637	59.6%	10,085	67.6%	279	14.0%	179	23.9%	37	48.7%	651	54.2%
Other specific carcinomas ^f	289	1.6%	238	1.6%	31	1.6%	-	-	-	-	17	1.4%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	646	3.6%	548	3.7%	54	2.7%	30	4.0%	-	-	46	3.8%
Other specific types ^g	44	0.2%	34	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	108	0.6%	95	0.6%	-	-	-	-	-	-	-	-
Total	17,844	100.0%	14,921	100.0%	1,997	100.0%	748	100.0%	76	100.0%	1,202	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^g Other specific types includes sarcomas and other soft tissue tumors.

Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	20,343	97.3%	14,247	97.0%	2,578	98.4%	3,203	97.9%	172	95.6%	3,258	95.9%
Hepatocellular carcinoma ^d (8170-8175)	15,936	76.2%	10,834	73.8%	2,196	83.8%	2,647	80.9%	140	77.8%	2,650	78.0%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560)	3,356	16.1%	2,665	18.1%	274	10.5%	377	11.5%	24	13.3%	453	13.3%
Other carcinoma ^e	1,051	5.0%	748	5.1%	108	4.1%	179	5.5%	-	-	155	4.6%
Other specific carcinoma ^f	645	3.1%	473	3.2%	53	2.0%	113	3.5%	-	-	95	2.8%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050)	406	1.9%	275	1.9%	55	2.1%	66	2.0%	-	-	60	1.8%
Hepatoblastoma (8970)	184	0.9%	146	1.0%	-	-	20	0.6%	-	-	69	2.0%
Sarcoma ^g	189	0.9%	153	1.0%	-	-	17	0.5%	-	-	31	0.9%
Hemangiosarcoma (9120)	72	0.3%	62	0.4%	-	-	-	-	-	-	-	-
Other sarcomas ^h	117	0.6%	91	0.6%	-	-	-	-	-	-	17	0.5%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100)	40	0.2%	24	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8004)	151	0.7%	116	0.8%	-	-	21	0.6%	-	-	30	0.9%
Total ^d	20,907	100.0%	14,686	100.0%	2,620	100.0%	3,271	100.0%	180	100.0%	3,398	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

^f Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^g Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^h Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

^h Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	221,882	98.9%	184,680	98.9%	23,929	98.9%	11,720	99.0%	726	97.2%	11,624	98.3%
Small cell (8041-8045)	30,639	13.7%	26,906	14.4%	2,561	10.6%	955	8.1%	134	17.9%	1,370	11.6%
Non-small cell ^d	191,243	85.2%	157,774	84.5%	21,368	88.3%	10,765	90.9%	592	79.3%	10,254	86.7%
Squamous and transitional cell ^e	46,659	20.8%	38,984	20.9%	5,549	22.9%	1,793	15.1%	179	24.0%	2,049	17.3%
Adenocarcinoma ^f	87,872	39.2%	72,009	38.6%	9,133	37.8%	6,175	52.1%	200	26.8%	5,036	42.6%
Large cell (8011-8015)	6,501	2.9%	5,316	2.8%	882	3.6%	265	2.2%	22	2.9%	324	2.7%
Other non-small cell ^g	50,211	22.4%	41,465	22.2%	5,804	24.0%	2,532	21.4%	191	25.6%	2,845	24.1%
Sarcoma ^h	402	0.2%	329	0.2%	42	0.2%	19	0.2%	-	-	41	0.3%
Other specified types ⁱ	181	0.1%	153	0.1%	20	0.1%	-	-	-	-	21	0.2%
Unspecified (8000-8005)	1,882	0.8%	1,561	0.8%	201	0.8%	97	0.8%	-	-	140	1.2%
Total	224,347	100.0%	186,723	100.0%	24,192	100.0%	11,844	100.0%	747	100.0%	11,826	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^e Squamous and transitional cell includes histologies 8051-8052, 8070-8084, 8120-8131.

^f Adenocarcinoma includes histologies 8050, 8140-8149, 8160-8162, 8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 8940-8941.

^g Other non-small cell includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas.

Other non-small cell is defined as histologies 8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671.

^h Sarcoma includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types includes melanomas and is defined as histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Males by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	118,537	98.9%	97,344	98.9%	13,613	99.0%	6,769	98.8%	376	97.4%	6,294	98.5%
Small cell (8041-8045)	15,380	12.8%	13,326	13.5%	1,313	9.5%	638	9.3%	62	16.1%	743	11.6%
Non-small cell ^d	103,157	86.0%	84,018	85.3%	12,300	89.4%	6,131	89.5%	314	81.3%	5,551	86.8%
Squamous and transitional cell ^e	29,478	24.6%	24,329	24.7%	3,590	26.1%	1,334	19.5%	111	28.8%	1,348	21.1%
Adenocarcinoma ^f	42,753	35.7%	34,617	35.2%	4,824	35.1%	3,058	44.6%	88	22.8%	2,439	38.2%
Large cell (8011-8015)	3,736	3.1%	3,031	3.1%	514	3.7%	172	2.5%	-	-	203	3.2%
Other non-small cell ^g	27,190	22.7%	22,041	22.4%	3,372	24.5%	1,567	22.9%	104	26.9%	1,561	24.4%
Sarcoma ^h	223	0.2%	183	0.2%	20	0.1%	-	-	-	-	18	0.3%
Other specified types ⁱ	102	0.1%	86	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	1,029	0.9%	837	0.9%	113	0.8%	65	0.9%	-	-	71	1.1%
Total	119,891	100.0%	98,450	100.0%	13,755	100.0%	6,854	100.0%	386	100.0%	6,393	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Squamous and transitional cell includes histologies 8051-8052, 8070-8084, 8120-8131.

^g Adenocarcinoma includes histologies 8050, 8140-8149, 8160-8162, 8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 8940-8941.

^h Other non-small cell includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas.

ⁱ Other non-small cell is defined as histologies 8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671.

^h Sarcoma includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types includes melanomas and is defined as histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	103,345	98.9%	87,336	98.9%	10,316	98.8%	4,951	99.2%	350	97.0%	5,330	98.1%
Small cell (8041-8045)	15,259	14.6%	13,580	15.4%	1,248	12.0%	317	6.4%	72	19.9%	627	11.5%
Non-small cell ^d	88,086	84.3%	73,756	83.6%	9,068	86.9%	4,634	92.9%	278	77.0%	4,703	86.6%
Squamous and transitional cell ^e	17,181	16.4%	14,655	16.6%	1,959	18.8%	459	9.2%	68	18.8%	701	12.9%
Adenocarcinoma ^f	45,119	43.2%	37,392	42.4%	4,309	41.3%	3,117	62.5%	112	31.0%	2,597	47.8%
Large cell (8011-8015)	2,765	2.6%	2,285	2.6%	368	3.5%	93	1.9%	-	-	121	2.2%
Other non-small cell ^g	23,021	22.0%	19,424	22.0%	2,432	23.3%	965	19.3%	87	24.1%	1,284	23.6%
Sarcoma ^h	179	0.2%	146	0.2%	22	0.2%	-	-	-	-	23	0.4%
Other specified types ⁱ	79	0.1%	67	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	853	0.8%	724	0.8%	88	0.8%	32	0.6%	-	-	69	1.3%
Total	104,456	100.0%	88,273	100.0%	10,437	100.0%	4,990	100.0%	361	100.0%	5,433	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Squamous and transitional cell includes histologies 8051-8052, 8070-8084, 8120-8131.

^g Adenocarcinoma includes histologies 8050, 8140-8149, 8160-8162, 8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 8940-8941.

^h Other non-small cell includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas.

ⁱ Other non-small cell is defined as histologies 8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671.

^h Sarcoma includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types includes melanomas and is defined as histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	37,218	83.3%	2,624	94.9%	12,576	96.7%	1,180	22.4%	2,365	95.5%
Squamous cell carcinoma (8070-8078,8083-8084)	36,225	81.0%	2,519	91.1%	12,363	95.1%	1,123	21.3%	2,337	94.3%
Adenocarcinoma ^c	4,826	10.8%	108	3.9%	211	1.6%	3,230	61.4%	88	3.6%
Other specific carcinomas ^d	524	1.2%	-	-	44	0.3%	286	5.4%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,600	3.6%	-	-	109	0.8%	366	7.0%	-	-
Sarcoma and soft tissue ^e	174	0.4%	-	-	23	0.2%	49	0.9%	-	-
Other specific types ^f	217	0.5%	-	-	-	-	95	1.8%	-	-
Unspecified (8000-8005)	144	0.3%	-	-	24	0.2%	56	1.1%	-	-
Total	44,703	100.0%	2,766	100.0%	12,999	100.0%	5,262	100.0%	2,477	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	4,918	80.0%	1,632	61.2%	8,670	97.0%	2,642	96.4%	611	86.8%
Squamous cell carcinoma (8070-8078,8083-8084)	4,678	76.1%	1,422	53.3%	8,560	95.8%	2,617	95.4%	606	86.1%
Adenocarcinoma ^c	1,004	16.3%	85	3.2%	63	0.7%	21	0.8%	16	2.3%
Other specific carcinomas ^d	37	0.6%	63	2.4%	42	0.5%	24	0.9%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	60	1.0%	823	30.9%	136	1.5%	40	1.5%	46	6.5%
Sarcoma and soft tissue ^e	31	0.5%	39	1.5%	-	-	-	-	-	-
Other specific types ^f	79	1.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	20	0.3%	-	-	-	-	-	-	-	-
Total	6,149	100.0%	2,667	100.0%	8,937	100.0%	2,742	100.0%	704	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,307	91.8%	20,549	92.3%	1,774	88.7%	1,687	89.9%	117	91.4%	2,666	87.5%
Epidermoid carcinoma ^d (8051-8131)	204	0.8%	160	0.7%	16	0.8%	23	1.2%	-	-	31	1.0%
Adenocarcinoma ^e	22,241	84.0%	18,870	84.7%	1,543	77.1%	1,562	83.3%	107	83.6%	2,385	78.3%
Adenocarcinoma, NOS (8140)	3,450	13.0%	2,852	12.8%	371	18.5%	196	10.4%	-	-	356	11.7%
Papillary adenocarcinoma, NOS (8050,8260)	511	1.9%	439	2.0%	48	2.4%	20	1.1%	-	-	47	1.5%
Clear cell adenocarcinoma (8310,9110)	1,331	5.0%	1,050	4.7%	42	2.1%	233	12.4%	-	-	124	4.1%
Endometrioid carcinoma (8380-8383,8570)	2,559	9.7%	2,190	9.8%	112	5.6%	220	11.7%	-	-	300	9.8%
Cystadenocarcinoma, NOS (8440,8450)	148	0.6%	118	0.5%	19	0.9%	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	4,318	16.3%	3,689	16.6%	281	14.0%	272	14.5%	35	27.3%	434	14.2%
Papillary serous cystadenocarcinoma (8460-8462)	7,113	26.9%	6,204	27.9%	489	24.4%	355	18.9%	33	25.8%	737	24.2%
Mucinous cystadenocarcinoma (8470-8473)	488	1.8%	404	1.8%	31	1.5%	40	2.1%	-	-	86	2.8%
Mucinous adenocarcinoma (8480,8482)	938	3.5%	743	3.3%	86	4.3%	98	5.2%	-	-	120	3.9%
Mucin-producing adenocarcinoma(8481)	71	0.3%	61	0.3%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,314	5.0%	1,120	5.0%	56	2.8%	119	6.3%	-	-	156	5.1%
Other specific carcinomas ^g	614	2.3%	467	2.1%	104	5.2%	32	1.7%	-	-	98	3.2%
Stromal cell tumor (8620-8631,8650)	379	1.4%	270	1.2%	78	3.9%	21	1.1%	-	-	60	2.0%
Other ^h	235	0.9%	197	0.9%	26	1.3%	-	-	-	-	38	1.2%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,248	4.7%	1,052	4.7%	111	5.5%	70	3.7%	-	-	152	5.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	99	0.4%	75	0.3%	17	0.8%	-	-	-	-	16	0.5%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,819	6.9%	1,435	6.4%	189	9.4%	169	9.0%	-	-	336	11.0%
Mullerian mixed tumor (8950-8951,8980)	766	2.9%	649	2.9%	64	3.2%	47	2.5%	-	-	66	2.2%
Teratoma, malignant (9080-9085,9102)	388	1.5%	281	1.3%	49	2.4%	52	2.8%	-	-	121	4.0%
Other	665	2.5%	505	2.3%	76	3.8%	70	3.7%	-	-	149	4.9%
Unspecified (8000-8005)	251	0.9%	211	0.9%	21	1.0%	-	-	-	-	28	0.9%
Total ^d	26,476	100.0%	22,270	100.0%	2,001	100.0%	1,876	100.0%	128	100.0%	3,046	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	38,146	97.9%	30,803	97.9%	4,519	98.0%	2,472	98.2%	167	97.1%	3,632	97.5%
Epidermoid carcinoma ^d (8051-8131)	73	0.2%	57	0.2%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	33,528	86.0%	27,096	86.1%	3,967	86.1%	2,164	86.0%	146	84.9%	3,167	85.0%
Adenocarcinoma, NOS (8140)	27,207	69.8%	21,957	69.8%	3,299	71.6%	1,697	67.4%	126	73.3%	2,579	69.2%
Papillary adenocarcinoma, NOS (8260)	68	0.2%	55	0.2%	-	-	-	-	-	-	16	0.4%
Mucinous adenocarcinoma (8480,8482)	1,052	2.7%	865	2.7%	107	2.3%	71	2.8%	-	-	94	2.5%
Mucin-producing adenocarcinoma (8481)	540	1.4%	433	1.4%	76	1.6%	28	1.1%	-	-	44	1.2%
Infiltrating duct carcinoma (8500-8503,8507,8514)	3,655	9.4%	2,965	9.4%	373	8.1%	295	11.7%	-	-	311	8.3%
Other adenocarcinoma ^f	1,006	2.6%	821	2.6%	107	2.3%	67	2.7%	-	-	123	3.3%
Other specific carcinomas ^g	2,296	5.9%	1,878	6.0%	256	5.6%	134	5.3%	-	-	221	5.9%
Islet cell carcinoma (8150-8155)	413	1.1%	343	1.1%	42	0.9%	24	1.0%	-	-	36	1.0%
Other carcinomas ^h	1,883	4.8%	1,535	4.9%	214	4.6%	110	4.4%	-	-	185	5.0%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	2,249	5.8%	1,772	5.6%	289	6.3%	167	6.6%	-	-	239	6.4%
Sarcoma and other soft tissue tumors ⁱ	29	0.1%	27	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	28	0.1%	19	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	761	2.0%	627	2.0%	82	1.8%	43	1.7%	-	-	84	2.3%
Total	38,965	100.0%	31,477	100.0%	4,610	100.0%	2,517	100.0%	172	100.0%	3,726	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	28,157	94.1%	19,985	94.6%	3,827	90.6%	3,953	95.2%	195	95.6%	4,750	96.5%
Epidermoid carcinoma ^d (8051-8131)	228	0.8%	156	0.7%	55	1.3%	16	0.4%	-	-	17	0.3%
Squamous cell carcinoma (8070-8078,8083-8084)	218	0.7%	150	0.7%	52	1.2%	-	-	-	-	-	-
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	25,475	85.1%	17,993	85.2%	3,409	80.7%	3,758	90.5%	176	86.3%	4,305	87.5%
Adenocarcinoma, NOS (8140)	14,728	49.2%	10,732	50.8%	2,011	47.6%	1,819	43.8%	93	45.6%	2,130	43.3%
Adenocarcinoma, intestinal type (8144)	2,453	8.2%	1,445	6.8%	348	8.2%	613	14.8%	31	15.2%	425	8.6%
Carcinoma, diffuse type (8145)	937	3.1%	592	2.8%	105	2.5%	229	5.5%	-	-	191	3.9%
Linitus plastica (8142)	247	0.8%	184	0.9%	30	0.7%	28	0.7%	-	-	61	1.2%
Mucinous adenocarcinoma (8470-8473,8480,8482)	437	1.5%	309	1.5%	76	1.8%	49	1.2%	-	-	60	1.2%
Mucin-producing adenocarcinoma (8481)	212	0.7%	166	0.8%	30	0.7%	16	0.4%	-	-	26	0.5%
Signet ring adenocarcinoma (8490)	5,262	17.6%	3,741	17.7%	670	15.9%	785	18.9%	34	16.7%	1,200	24.4%
Other adenocarcinomas ^e	1,199	4.0%	824	3.9%	139	3.3%	219	5.3%	-	-	212	4.3%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	1,690	5.6%	1,298	6.1%	237	5.6%	92	2.2%	-	-	300	6.1%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	764	2.6%	538	2.5%	126	3.0%	87	2.1%	-	-	128	2.6%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	73	0.2%	55	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	1,554	5.2%	991	4.7%	370	8.8%	173	4.2%	-	-	146	3.0%
Unspecified (8000-8005)	136	0.5%	94	0.4%	-	-	23	0.6%	-	-	17	0.3%
Total ^d	29,921	100.0%	21,126	100.0%	4,224	100.0%	4,152	100.0%	204	100.0%	4,922	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2005-2009
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	48,423	99.7%	39,766	99.7%	3,098	99.4%	4,592	99.8%	188	99.5%	6,828	99.8%
Epidermoid carcinoma ^d (8051-8131)	58	0.1%	50	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	46,764	96.3%	38,406	96.3%	2,953	94.8%	4,477	97.3%	178	94.2%	6,609	96.6%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	42,074	86.6%	34,665	86.9%	2,460	78.9%	4,116	89.4%	160	84.7%	6,114	89.4%
Follicular carcinoma (8330-8332,8335)	2,991	6.2%	2,305	5.8%	356	11.4%	259	5.6%	17	9.0%	328	4.8%
Oxyphilic (8290)	1,349	2.8%	1,153	2.9%	105	3.4%	77	1.7%	-	-	128	1.9%
Other specific carcinomas ^f	869	1.8%	727	1.8%	83	2.7%	36	0.8%	-	-	126	1.8%
Medullary carcinoma (8510)	831	1.7%	695	1.7%	79	2.5%	35	0.8%	-	-	122	1.8%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	732	1.5%	583	1.5%	59	1.9%	76	1.7%	-	-	85	1.2%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	445	0.9%	356	0.9%	35	1.1%	48	1.0%	-	-	49	0.7%
Sarcoma and other soft tissue tumors ^g	-	-	-	-	-	-	-	-	-	-	-	-
Other specific types ^h	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	131	0.3%	100	0.3%	-	-	-	-	-	-	-	-
Total	48,567	100.0%	39,874	100.0%	3,116	100.0%	4,602	100.0%	189	100.0%	6,841	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^h Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.